Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's Phase 3 semaglutide Alzheimer's trials.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

That’s because the body fights back against weight loss after the drug’s effects wear off. As you lose weight because of drug ...